What did this study look at?
Pfizer worked with Sick Cells to develop a survey to understand how much different features of potential sickle cell treatments matter to people with sickle cell disease (SCD) and caregivers of people with SCD. The results from this survey will help Pfizer:
- Design clinical trials that measure what matters to patients and caregivers
- Make sure they are developing treatments that meet the needs of people with sickle cell disease and their caregivers
Pfizer partnered with Sick Cells to gather this information. The survey was open from February 21, 2022, to April 21, 2022.
What information did the survey capture?
In this survey, people were asked 6 different questions called point-allocation questions (see example question on next page). In each question, people were shown 5 or 6 items that could be associated with a treatment for sickle cell disease. A total of 26 items were shown to respondents. They were asked to give points to each item to show how important they think it is that a sickle cell treatment has that item.
- If an item was more important, they gave more points to it.
- If an item was less important, they gave fewer points to it.
- If an item was not at all important, they could give zero (0) points to it.
They had 100 points to give to items in each question so that the total number of points across all items in a question added up to 100.
Click the button below to view the final summary and results of the survey.